DYAI

Dyadic International, Inc. [DYAI] Stock Forecast

Q: What is Dyadic International, Inc. stock symbol ?

Dyadic International, Inc. is a US stock, located in Jupiter of Fl and trading under the symbol DYAI

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

DYAI Stock Summary

Earnings have grown 21.9% per last year.

Earnings are expected to rise 108.17% next year

The Moving Average Convergence Divergence (MACD) for DYAI recently turned positive (within last 10 days).

Currently unprofitable, and not expected to turn profitable in the coming year

DYAI has less than 1 year of cash runway

Top 10 Correlated ETFs

DYAI

Top 10 Correlated Stocks

DYAI

In the News

11:23 30 Nov 2023 DYAI

Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript

Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Paul Rosenbaum - SWR Operator Good evening, and welcome to the Dyadic International's Third Quarter 2023 Financial Results Conference Call. Currently all participants are in a listen-only mode.

08:30 30 Nov 2023 DYAI

Dyadic to Present at Industry Events in November

JUPITER, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating and presenting at the following industry events during the month of November: Cultured Meat Symposium 2023, November 2-3, 2023StarBase, Las VegasJoseph Hazelton, Chief Business Officer 8th International Vaccines Research & Development, November 6-8, 2023Hilton Baltimore BWI Airport Hotel, Linthicum Heights, MDMark Emalfarb, President, and Chief Executive Officer “Next-Gen Vaccines without the Right Platform Limit Pandemic Effectiveness C1, Protective, Rapid, High Yield, Low-Cost Global Solution” Presentation Time: Monday, November 6, 2023, 2:10 PM – 2:30 PM ET BARDA Industry Day 2023, November 13-14, 2023Grand Hyatt Washington, Washington, DCJoseph Hazelton, Chief Business Officer Vaccines Summit, November 13-15, 2023Sheraton Boston Needham Hotel, Boston, MAMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale of complex recombinant proteins and antigens including ferritin nanoparticles for infectious diseases including COVID-19 and seasonal and pandemic influenza” Presentation Time: Wednesday, November 15, 2023, 1:40 PM – 2:00 PM ET If you would like to connect with Dyadic's management at any of these events, you may request a one-on-one meeting at jlavalley@dyadic.com About Dyadic International, Inc. Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.

04:30 30 Nov 2023 DYAI

Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the third quarter 2023 and host a corporate update conference call on Wednesday, November 8, 2023.

08:30 30 Nov 2023 DYAI

Dyadic to Present at Industry and Investor Events in October

JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be presenting at the following industry and investor events during the month of October: Enzyme Engineering XXVII, October 1-6, 2023Park Royal Hotel, SingaporeDr. Ronen Tchelet, Chief Scientific Officer “The use of in silico analysis to engineer the best immunogenic epitope and produce the corresponding prophylactic antigen-based vaccines with C1 production platform in order to rapidly respond to viral pandemics” Wednesday, October 4, 2023, 11:00 AM – 11:30 AM LD Mirco Main Event XVI, October 3-5, 2023Luxe Sunset Blvd Hotel, Los Angeles, CAMark Emalfarb, President, and Chief Executive Officer “Next Generation Proteins for World Health, Nutrition and Wellness” Wednesday, October 4, 2023, 8:00 AM – 8:25 AM World Vaccine Congress Europe, October 16-19, 2023Fira de Barcelona Montjuic, Barcelona, SpainMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale manufacturing of complex recombinant proteins and antigens including ferritin nanoparticles for seasonal and pandemic influenza vaccines” Wednesday, October 18, 2023, 11:45 AM – 12:00 PM If you would like to connect with Dyadic's management at any of the events, you may request a one-on-one meeting at jlavalley@dyadic.com.

04:30 30 Nov 2023 DYAI

Dyadic to Present at BioProcess International

JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.

11:41 30 Nov 2023 DYAI

Dyadic International, Inc. (DYAI) Q2 2023 Earnings Call Transcript

Dyadic International, Inc. (NASDAQ:DYAI ) Q2 2023 Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Dick Williams - Williams Research Group Robert Smith - Center for Performance Investing Tony Bowers - Intro Act Operator Good evening, and welcome to Dyadic International's Second Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

04:30 30 Nov 2023 DYAI

Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the second quarter 2023 and host a corporate update conference call on Wednesday, August 9, 2023.

10:19 30 Nov 2023 DYAI

Dyadic International, Inc. (DYAI) Q1 2023 Earnings Call Transcript

Dyadic International, Inc. (NASDAQ:DYAI ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Operator Good evening, and welcome to Dyadic International's First Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

04:30 30 Nov 2023 DYAI

Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a corporate update conference call on Wednesday, May 10, 2023.

09:51 30 Nov 2023 DYAI

Dyadic reports 21.9% revenue rise, $12.7M in cash for full year 2022 as it rapidly advances technology

Dyadic International Inc (NASDAQ:DYAI) posted its financial results for the year ended 2022 with revenue surging 21.9% year-over-year on the back of license agreements as it rapidly advanced its technology. For the year ended December 31, 2022, the Jupiter, Florida-based biotechnology platform company reported research and development (R&D) revenue of $2.93 million, compared to $2.40 million for the year ended December 31, 2021.

DYAI Financial details

Company Rating

Neutral

Market Cap

54.16M

Income

-5.7M

Revenue

2.96M

Book val./share

0.27

Cash/share

0.28

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

08 Nov 2023

P/E

-8.92

Forward P/E

7.08

PEG

1.57

P/S

17.2

P/B

6.65

P/C

6.32

P/FCF

-6.79

Quick Ratio

5.9

Current Ratio

6.24

Debt / Equity

0.02

LT Debt / Equity

0.01

EPS (TTM)

-0.2

EPS next Y

0.25

EPS next Q

-0.06

EPS this Y

-28.26%

EPS next Y

-225.63%

EPS next 5Y

85.93%

EPS last 5Y

9.46%

Revenue last 5Y

17.73%

Revenue Q/Q

-52.57%

EPS Q/Q

-25.03%

SMA20

SMA50

SMA100

Inst Own

12.19%

Inst Trans

0.78%

ROA

-62%

ROE

-59%

ROC

-1.06%

Gross Margin

21%

Oper. Margin

-280%

Profit Margin

-193%

Payout

Shs Outstand

28.81M

Shs Float

18.7M

Target Price

52W Range

1.12-2.4

52W High

-11.5%

52W Low

+77%

RSI

Rel Volume

0.96

Avg Volume

24.29K

Volume

23.39K

Perf Week

-2.21%

Perf Month

-1.12%

Perf Quarter

-20.27%

Perf Half Y

-20.63%

Beta

0.616

Volatility

0.04%, 0.08%

Prev Close

0.28%

Price

1.77

Change

-3.01%

DYAI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.05	0.06	0.06	0.09	0.1
Net income per share	-0.21	-0.31	-0.34	-0.46	-0.33
Operating cash flow per share	-0.16	-0.21	-0.24	-0.41	-0.28
Free cash flow per share	-0.16	-0.21	-0.24	-0.41	-0.28
Cash per share	1.49	1.27	1.06	0.73	0.45
Book value per share	1.53	1.33	1.04	0.66	0.39
Tangible book value per share	1.53	1.33	1.04	0.66	0.39
Share holders equity per share	1.53	1.33	1.04	0.66	0.39
Interest debt per share	0.03	0	0	0	-0.01
Market cap	52.3M	139.88M	147.8M	125.83M	34.89M
Enterprise value	49.92M	135.06M	127.16M	110.08M	29.09M
P/E ratio	-9.19	-16.84	-15.85	-9.74	-3.72
Price to sales ratio	40.37	83.21	92.26	52.34	11.91
POCF ratio	-11.87	-24.19	-22.48	-11.16	-4.32
PFCF ratio	-11.87	-24.19	-22.48	-11.16	-4.32
P/B Ratio	1.23	3.9	5.2	6.84	3.15
PTB ratio	1.23	3.9	5.2	6.84	3.15
EV to sales	38.53	80.34	79.38	45.79	9.93
Enterprise value over EBITDA	-6.61	-14.64	-12.48	-6.82	-2.89
EV to operating cash flow	-11.33	-23.35	-19.34	-9.76	-3.6
EV to free cash flow	-11.33	-23.35	-19.34	-9.76	-3.6
Earnings yield	-0.11	-0.06	-0.06	-0.1	-0.27
Free cash flow yield	-0.08	-0.04	-0.04	-0.09	-0.23
Debt to equity	0	0	0	0	0
Debt to assets	0	0	0	0	0
Net debt to EBITDA	0.32	0.52	2.03	0.98	0.58
Current ratio	50.31	22.44	18.32	8.22	5.48
Interest coverage	-8.49	0	0	0	26.59
Income quality	0.77	0.7	0.71	0.86	0.83
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	3.49	3.28	3.8	2.79	2.19
Research and developement to revenue	2.56	2.35	2.41	3.49	1.54
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0.36	0.7	1.03	0.74	0.64
Graham number	2.66	3.03	2.81	2.63	1.7
ROIC	-0.15	-0.26	-0.35	-0.79	-0.88
Return on tangible assets	-0.13	-0.22	-0.31	-0.61	-0.68
Graham Net	1.49	1.24	1.01	0.63	0.36
Working capital	41.9M	34.05M	28.16M	18.45M	10.97M
Tangible asset value	42.45M	35.86M	28.45M	18.39M	11.09M
Net current asset value	41.9M	34.05M	28.16M	18.1M	10.8M
Invested capital	0	0	0	0	0
Average receivables	940.36K	1.13M	772.5K	389.33K	380.25K
Average payables	414.66K	626.22K	978.24K	1.28M	1.41M
Average inventory	634.32K	126.72K	0	0	0
Days sales outstanding	315.52	247.2	92.61	56.52	48.37
Days payables outstanding	109.81	235.89	259.51	290.57	219.41
Days of inventory on hand	90.05	0	0	0	0
Receivables turnover	1.16	1.48	3.94	6.46	7.55
Payables turnover	3.32	1.55	1.41	1.26	1.66
Inventory turnover	4.05	0	0	0	0
ROE	-0.13	-0.23	-0.33	-0.7	-0.85
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.03	0.03	0.03	0.03	0.01
Net income per share	-0.06	-0.07	0	-0.07	-0.06
Operating cash flow per share	-0.06	-0.06	-0.08	-0.06	-0.07
Free cash flow per share	-0.06	-0.06	-0.08	-0.06	-0.07
Cash per share	0.5	0.45	0.41	0.35	0.28
Book value per share	0.44	0.39	0.38	0.31	0.27
Tangible book value per share	0.44	0.39	0.38	0.31	0.27
Share holders equity per share	0.44	0.39	0.38	0.31	0.27
Interest debt per share	0	0	-0.04	0	0.01
Market cap	54.23M	34.89M	51.2M	55.61M	55.32M
Enterprise value	47.49M	29.09M	44.82M	49.76M	48.06M
P/E ratio	-7.97	-4.21	93.01	-6.46	-8.57
Price to sales ratio	61.65	46.91	52.34	66.42	139.32
POCF ratio	-30.53	-20.75	-23.41	-33.6	-28.2
PFCF ratio	-30.53	-20.75	-23.41	-33.6	-28.2
P/B Ratio	4.3	3.15	4.74	6.19	7.23
PTB ratio	4.3	3.15	4.74	6.19	7.23
EV to sales	53.99	39.12	45.83	59.44	121.05
Enterprise value over EBITDA	-25.85	-13.3	-22.1	-22.01	-28.36
EV to operating cash flow	-26.74	-17.3	-20.5	-30.07	-24.5
EV to free cash flow	-26.74	-17.3	-20.5	-30.07	-24.5
Earnings yield	-0.03	-0.06	0	-0.04	-0.03
Free cash flow yield	-0.03	-0.05	-0.04	-0.03	-0.04
Debt to equity	0	0	0	0	0.02
Debt to assets	0	0	0	0	0.02
Net debt to EBITDA	3.67	2.65	3.14	2.58	4.28
Current ratio	6.25	5.48	6.83	5.53	6.24
Interest coverage	-34.32	33.13	1.87	0	0
Income quality	0.98	0.78	2.29	0.77	1.22
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.57	2.24	1.51	1.68	3.23
Research and developement to revenue	0.85	0.79	0.83	1.1	1.8
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0.57	0.65	0.34	0.4	0.71
Graham number	0.77	0.8	0.2	0.72	0.58
ROIC	-0.14	-0.19	0.03	-0.24	-0.2
Return on tangible assets	-0.11	-0.15	0.01	-0.19	-0.17
Graham Net	0.42	0.36	0.36	0.3	0.24
Working capital	12.54M	10.97M	10.93M	9.07M	7.63M
Tangible asset value	12.61M	11.09M	10.8M	8.99M	7.65M
Net current asset value	12.32M	10.8M	10.8M	8.98M	7.48M
Invested capital	0	0	0	0	0.02
Average receivables	733.46K	333.76K	586.23K	793.91K	615.68K
Average payables	936.22K	1.03M	1.02M	838.12K	753.01K
Average inventory	0	0	0	0	0
Days sales outstanding	28.57	46.99	72.16	86.4	96.95
Days payables outstanding	116.04	163.05	95.38	102.82	510.19
Days of inventory on hand	0	0	0	0	0
Receivables turnover	3.15	1.92	1.25	1.04	0.93
Payables turnover	0.78	0.55	0.94	0.88	0.18
Inventory turnover	0	0	0	0	0
ROE	-0.13	-0.19	0.01	-0.24	-0.21
Capex per share	0	0	0	0	0

DYAI Frequently Asked Questions

What is Dyadic International, Inc. stock symbol ?

Dyadic International, Inc. is a US stock , located in Jupiter of Fl and trading under the symbol DYAI

What is Dyadic International, Inc. stock quote today ?

Dyadic International, Inc. stock price is $1.77 today.

Is Dyadic International, Inc. stock public?

Yes, Dyadic International, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 24.29K
Market Capitalization 54.16M
Employee 7
CEO Mr. Mark A. Emalfarb
Headquarters Jupiter,FL,US
IPO Date 2008-01-16
Website https://www.dyadic.com

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.